Tetraphase Pharmaceuticals, Inc. (TTPH) EPS Estimated At $-0.64; Sykes Enterprises (SYKE) Sellers Decreased By 13.58% Their Shorts

February 15, 2018 - By Peter Erickson

Analysts expect Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) to report $-0.64 EPS on March, 14.They anticipate $0.03 EPS change or 4.92% from last quarter’s $-0.61 EPS. After having $-0.63 EPS previously, Tetraphase Pharmaceuticals, Inc.’s analysts see 1.59% EPS growth. The stock decreased 60.41% or $3.28 during the last trading session, reaching $2.15. About 16.86 million shares traded or 2122.67% up from the average. Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) has risen 106.58% since February 15, 2017 and is uptrending. It has outperformed by 89.88% the S&P500.

Sykes Enterprises (NASDAQ:SYKE) had a decrease of 13.58% in short interest. SYKE’s SI was 1.17 million shares in February as released by FINRA. Its down 13.58% from 1.35M shares previously. With 251,800 avg volume, 5 days are for Sykes Enterprises (NASDAQ:SYKE)’s short sellers to cover SYKE’s short positions. The SI to Sykes Enterprises’s float is 3.05%. The stock increased 0.73% or $0.21 during the last trading session, reaching $29.12. About 171,856 shares traded or 5.22% up from the average. Sykes Enterprises, Incorporated (NASDAQ:SYKE) has risen 14.01% since February 15, 2017 and is uptrending. It has underperformed by 2.69% the S&P500.

Since August 30, 2017, it had 0 buys, and 1 sale for $525,480 activity. Sykes Charles E had sold 20,000 shares worth $525,480 on Wednesday, August 30.

Investors sentiment increased to 1.39 in 2017 Q3. Its up 0.42, from 0.97 in 2017Q2. It is positive, as 20 investors sold Sykes Enterprises, Incorporated shares while 42 reduced holdings. 22 funds opened positions while 64 raised stakes. 36.50 million shares or 0.07% more from 36.48 million shares in 2017Q2 were reported. First Personal Fin Serv reported 250 shares or 0% of all its holdings. Ameriprise holds 208,874 shares or 0% of its portfolio. Metropolitan Life Ins reported 26,594 shares. Mason Street Advsrs Ltd Com reported 0.01% of its portfolio in Sykes Enterprises, Incorporated (NASDAQ:SYKE). Moreover, Texas Permanent School Fund has 0.01% invested in Sykes Enterprises, Incorporated (NASDAQ:SYKE). Envestnet Asset invested in 10,828 shares. Pub Employees Retirement Association Of Colorado holds 8,137 shares or 0% of its portfolio. Td Asset Management has 109,700 shares. The Minnesota-based Us National Bank & Trust De has invested 0% in Sykes Enterprises, Incorporated (NASDAQ:SYKE). Los Angeles Cap Mngmt And Equity Rech holds 0.01% or 33,260 shares. Parkside National Bank & Trust Trust, a Missouri-based fund reported 1,316 shares. Citigroup Inc reported 34,815 shares stake. 58,585 were accumulated by Convergence Invest. Panagora Asset Mgmt has 0% invested in Sykes Enterprises, Incorporated (NASDAQ:SYKE) for 2,800 shares. New York State Teachers Retirement has invested 0.01% in Sykes Enterprises, Incorporated (NASDAQ:SYKE).

Sykes Enterprises, Incorporated, together with its subsidiaries, provides business process outsourcing solutions. The company has market cap of $1.24 billion. The Company’s customer care services include product information requests, describing product features, activating customer accounts, resolving complaints, cross-selling/up-selling, handling billing inquiries, changing addresses, claims handling, ordering/reservations, prequalification and warranty management, providing health information, and roadside assistance. It has a 18.2 P/E ratio. The companyÂ’s technical support services comprise handling inquiries regarding hardware, software, communications services, communications equipment, Internet access technology, and Internet portal usage; and customer acquisition services focuses around digital marketing, demand generation, and in-bound sales conversion, as well as inbound and outbound up-selling its clientsÂ’ services and products.

Among 5 analysts covering Sykes Enterprises (NASDAQ:SYKE), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Sykes Enterprises had 9 analyst reports since August 5, 2015 according to SRatingsIntel. The stock has “Mkt Perform” rating by Barrington Research on Wednesday, January 20. Robert W. Baird maintained Sykes Enterprises, Incorporated (NASDAQ:SYKE) rating on Friday, October 20. Robert W. Baird has “Hold” rating and $29.0 target. The rating was maintained by SunTrust on Monday, October 9 with “Buy”. As per Wednesday, August 5, the company rating was downgraded by Zacks. Robert W. Baird maintained Sykes Enterprises, Incorporated (NASDAQ:SYKE) on Friday, September 15 with “Hold” rating. The company was upgraded on Tuesday, March 8 by Craig Hallum. Sidoti initiated the shares of SYKE in report on Tuesday, January 17 with “Buy” rating. The firm has “Neutral” rating by Robert W. Baird given on Tuesday, August 8.

Investors sentiment increased to 2.21 in Q3 2017. Its up 0.90, from 1.31 in 2017Q2. It is positive, as 10 investors sold Tetraphase Pharmaceuticals, Inc. shares while 14 reduced holdings. 19 funds opened positions while 34 raised stakes. 29.38 million shares or 42.90% more from 20.56 million shares in 2017Q2 were reported. California Employees Retirement System, California-based fund reported 242,200 shares. 122,422 were reported by Tiaa Cref Invest Management Limited Liability Com. Bnp Paribas Arbitrage Sa holds 0% of its portfolio in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) for 3,498 shares. Deutsche National Bank Ag accumulated 0% or 82,429 shares. American Group Inc stated it has 0% of its portfolio in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). 110,461 were accumulated by Barclays Public Ltd Com. Hudson Bay Cap Mngmt Ltd Partnership owns 560,000 shares or 0.1% of their US portfolio. Group Incorporated One Trading Ltd Partnership reported 121,364 shares. Moreover, Millennium Mngmt Limited Liability Company has 0.02% invested in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Eventide Asset Mngmt Ltd Llc owns 463,700 shares for 0.18% of their portfolio. State Board Of Administration Of Florida Retirement holds 0% in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) or 19,923 shares. Teton Advsrs holds 0.02% or 30,000 shares. State Street accumulated 930,274 shares. Ellington Mngmt Gp Ltd owns 0.02% invested in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) for 20,600 shares. Goldman Sachs Group Inc Inc holds 47,051 shares or 0% of its portfolio.

Among 15 analysts covering Tetraphase Pharmaceuticals (NASDAQ:TTPH), 6 have Buy rating, 0 Sell and 9 Hold. Therefore 40% are positive. Tetraphase Pharmaceuticals had 29 analyst reports since August 6, 2015 according to SRatingsIntel. Stifel Nicolaus upgraded the stock to “Buy” rating in Wednesday, July 26 report. Needham maintained Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) rating on Thursday, August 6. Needham has “Buy” rating and $56 target. SunTrust maintained Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) on Wednesday, February 14 with “Buy” rating. The firm has “Hold” rating given on Wednesday, September 9 by Brean Capital. The stock of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) has “Neutral” rating given on Wednesday, September 9 by SunTrust. As per Monday, February 12, the company rating was initiated by FBR Capital. The firm has “Buy” rating given on Thursday, November 19 by SunTrust. As per Thursday, October 5, the company rating was maintained by BMO Capital Markets. The stock has “Hold” rating by Needham on Thursday, August 3. The rating was downgraded by JMP Securities to “Market Perform” on Wednesday, September 9.

Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company has market cap of $110.93 million. The Company’s lead product candidate is eravacycline, an intravenous and oral antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It currently has negative earnings. The firm has completed a Phase III clinical trial of eravacycline with intravenous administration for the treatment of complicated intra-abdominal infections; and initiated a Phase III clinical trial of eravacycline for the treatment of complicated urinary tract infections with intravenous-to- oral transition therapy.

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>